WAYS TO IMPROVE THE SYSTEM OF FINANCIAL INCLUSION OF MEDICATIONS FOR POPULATION OF THE RUSSIAN FEDERATION
https://doi.org/10.17238/PmJ1609-1175.2019.2.28-32
Abstract
Objective is to define determinants of financial inclusion of medications to treat diseases of cardiovascular system after enaction of state price registration.
Methods: To assess the cost per unit it was used an approach based on defined daily dose (DDD). For the study we selected basic medications intended to treat disease of cardiovascular system (category АТХ). According to DDD we calculated the price DDD (pDDD). For the analysis we created a database of registered prices for medications of pharma producers for 2010–2016. We determined the evaluations of general totality, maximal and minimal rate and dynamics of prices during test period.
Results: It was established that movement of medications prices from 2010 to 2016 had been ambiguously changing and had been similar to rates of Federal State Statistics Service, but since 2015 difference have been registered as well.
Conclusion: It is necessary to improve the system of financial inclusion of medications for the population to treat cardiovascular diseases.
About the Authors
R. Kh. Khafisianova
Kazan State Medical University
Russian Federation
49 Butlorov St. Kazan 420012 Russian Federation
Russian Federation
49 Butlorov St. Kazan 420012 Russian Federation
I. M. Burykin
Kazan State Medical University
Russian Federation
49 Butlorov St. Kazan 420012 Russian Federation
Russian Federation
49 Butlorov St. Kazan 420012 Russian Federation
G. N. Aleeva
Nizhpharm Joint-Stock Company
Russian Federation
Russian Federation
7 Salganskaya St. Nizhny Novgorod 603950 Russian Federation
References
1. Introduction to drug utilization research. Geneva: WHO, 2003. 84 p.
2. Cameron A., Ewen M., Ross-Degnan D. [et al.]. Medicine prices, availability, and affordability in 36 developing and middleincome countries: a secondary analysis // Lancet. 2009. Vol. 373, No. 9659. P. 240–249.
3. Aleeva G.N., Zhuravleva M.V., Burykin I.M. Pharmacoeconomical analysis of the effectiveness of cardiostatin in the treatment of hypercholesterolemia // Clinical Pharmacology and Therapy. 2009. No. 6. P. 72–73.
4. Kanavos P., Reinhardt U. Reference pricing for drugs: Is it compatible with U.S. Health Care? // Health Aff. 2003. Vol. 22, No. 3. P. 16–30.
5. VNOK. National Clinical Guidelines. Moscow: Silitseya-Poligraf, 2008. 512 p.
6. How to develop and implement a national drug policy. 2nd ed. Geneva: World Health Organization, 2001. 83 p.
7. Introduction to drug utilization research. Geneva: WHO, 2003. 84 p.
8. Ziganshina L.E., Magsumova D.R., Kuchaeva A.V. [et al.]. ATC/DDD classification system in pharmacoepidemiological studies // Qualitative Clinical Practice. 2004. No. 1. P. 28–33.
9. Kanavos P., Reinhardt U. Reference pricing for drugs: Is it compatible with U.S. Health Care? // Health Aff. 2003. Vol. 22, No. 3. P. 16–30.
10. Kontsevaya A.V., Kalinina A.M., Koltunov E.I., Oganov R.G. Socio-economic damage from acute coronary syndrome in the Russian Federation // Rational Pharmacotherapy in Cardiology. 2011. Vol. 2, No. 7. P. 158–166.
11. Lozovskaya A. Why is the availability of medicines for the population
12. reduced? // Pharmacy business. 2011. No. 1–2.
13. Smolina V.A., Pashko O.D. Availability of pharmaceutical care to the population of Saratov region // Bulletin of Medical Internet Conferences. 2013. Vol. 3, No. 12. P. 1362–1364.
14. Tkachenko O.V. The selection, purchase and consumption of drugs: the experience of sociological research // Modern Research of Social Problems. 2013. No. 6. doi: 10.12731/2218-7405-2013-6-53 (date of access: 23.01.2019).
15. Khafizyanova R.Kh., Burykin I.M., Aleeva G.N. Mathematical statistics in experimental and clinical pharmacology. Kazan: Meditsina. 2006. 374 p.
16. Cameron A., Ewen M., Ross-Degnan D. [et al.]. Medicine prices, availability, and affordability in 36 developing and middleincome countries: a secondary analysis // Lancet. 2009. Vol. 373, No. 9659. P. 240–249.
17. How to develop and implement a national drug policy. 2nd ed. Geneva: World Health Organization, 2001. 83 p.
18. Introduction to drug utilization research. Geneva: WHO, 2003. 84 p.
19. Kanavos P., Reinhardt U. Reference pricing for drugs: Is it compatible with U.S. Health Care? // Health Aff. 2003. Vol. 22, No. 3. P. 16–30.
Review
For citations:
Khafisianova R.Kh., Burykin I.M., Aleeva G.N. WAYS TO IMPROVE THE SYSTEM OF FINANCIAL INCLUSION OF MEDICATIONS FOR POPULATION OF THE RUSSIAN FEDERATION. Pacific Medical Journal. 2019;(2):28-32. (In Russ.) https://doi.org/10.17238/PmJ1609-1175.2019.2.28-32
Views:
305
Email this article 